



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

## Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan

Procedural steps taken and scientific information after the authorisation

| Application number | Scope  | Opinion/ Notification <sup>1</sup> issued on | Commission Decision Issued <sup>2</sup> / amended on | Product Information affected <sup>3</sup> | Summary |
|--------------------|--|--|--|---|---------|
| IB/0027/G          | This was an application for a group of variations.<br><br>B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes | 03/11/2023                                   |  | SmPC,<br>Labelling and<br>PL              |         |

<sup>1</sup> Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

<sup>2</sup> A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

<sup>3</sup> SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).



|           |   |            |     |  |  |
|-----------|---|------------|-----|--|--|
|           | <p>B.II.e.4.a - Change in shape or dimensions of the container or closure (immediate packaging) - Non-sterile medicinal products</p> <p>B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes</p> <p>B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes</p> <p>B.II.e.1.b.1 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Solid, semi-solid and non-sterile liquid pharmaceutical forms</p> <p>B.II.e.6.a - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that affects the product information</p> |            |     |  |  |
| IA/0026/G | <p>This was an application for a group of variations.</p> <p>A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient</p> <p>B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure</p>   | 01/09/2023 | n/a |  |  |

|           |  |            |            |             |  |
|-----------|--|------------|------------|-------------|--|
| II/0025   | B.I.z - Quality change - Active substance - Other variation  | 31/08/2023 | n/a        |             |  |
| IAIN/0024 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation   | 30/05/2023 | 15/09/2023 | SmPC and PL |  |
| IB/0023/G | <p>This was an application for a group of variations.</p> <p>B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF</p> <p>B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)</p> | 04/10/2022 | n/a        |             |  |
| IB/0020   | C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation   | 22/08/2022 | 15/09/2023 | SmPC and PL |  |
| IA/0022/G | <p>This was an application for a group of variations.</p> <p>B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits</p> <p>B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of</p>                                       | 13/07/2022 | n/a        |             |  |

|         |  |            |            |  |  |
|---------|--|------------|------------|--|--|
|         | <p>specification limits</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p> <p>B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)</p> <p>B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method</p> <p>B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method</p> <p>B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method</p> <p>A.7 - Administrative change - Deletion of manufacturing sites</p> |            |            |  |  |
| IA/0021 | A.7 - Administrative change - Deletion of manufacturing sites  | 27/06/2022 | n/a        |  |  |
| R/0019  | Renewal of the marketing authorisation.  | 24/03/2022 | 24/05/2022 |  |  |

|           |  |            |            |                              |  |
|-----------|--|------------|------------|------------------------------|--|
| T/0018    | Transfer of Marketing Authorisation  | 15/09/2021 | 29/09/2021 | SmPC,<br>Labelling and<br>PL |  |
| IB/0017   | C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation   | 22/07/2021 | 29/09/2021 | SmPC and PL                  |  |
| II/0015/G | <p>This was an application for a group of variations.</p> <p>B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits</p> <p>B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)</p> <p>B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size</p> <p>A.7 - Administrative change - Deletion of manufacturing sites</p> <p>A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient</p> | 22/07/2021 | n/a        |                              |  |

|           |   |            |            |                        |  |
|-----------|---|------------|------------|------------------------|--|
|           | <p>B.I.d.1.a.1 - Stability of AS - Change in the re-test period/storage period - Reduction</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p> <p>B.I.z - Quality change - Active substance - Other variation</p> <p>B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer</p> |            |            |                        |  |
| IB/0016   | C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation  | 18/04/2021 | 29/09/2021 | SmPC and PL            |  |
| IA/0014   | A.7 - Administrative change - Deletion of manufacturing sites   | 23/02/2021 | 29/09/2021 | Annex II and PL        |  |
| IB/0013/G | <p>This was an application for a group of variations.</p> <p>C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by</p>   | 11/02/2021 | 29/09/2021 | SmPC, Labelling and PL |  |

|             |   |            |            |                 |  |
|-------------|---|------------|------------|-----------------|--|
|             | <p>the MAH</p> <p>C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH</p>  |            |            |                 |  |
| IAIN/0012/G | <p>This was an application for a group of variations.</p> <p>B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing</p> <p>B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing</p> | 19/06/2020 | 18/11/2020 | Annex II and PL |  |
| IB/0011/G   | <p>This was an application for a group of variations.</p> <p>A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient</p> <p>A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or</p>   | 17/06/2020 | n/a        |                 |  |

|   |  |  |  |  |
|---|--|--|--|--|
| <p>intermediate used in the manufacture of the AS or manufacturer of a novel excipient</p> <p>B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation</p> <p>B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF</p> <p>B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)</p> <p>A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient</p> <p>A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient</p> <p>A.7 - Administrative change - Deletion of manufacturing sites</p> <p>B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation</p> <p>B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation</p> <p>B.I.a.2.e - Changes in the manufacturing process of</p> |  |  |  |  |
|---|--|--|--|--|



|           |  |            |            |                        |  |
|-----------|--|------------|------------|------------------------|--|
|           | the AS - Minor change to the restricted part of an ASMF<br>B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF   |            |            |                        |  |
| IB/0010   | C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation   | 14/05/2020 | 18/11/2020 | SmPC and PL            |  |
| IB/0009   | B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes  | 27/02/2020 | 18/11/2020 | SmPC, Labelling and PL |  |
| IB/0008   | B.II.f.1.b.2 - Stability of FP - Extension of the shelf life of the finished product - After first opening (supported by real time data)   | 05/12/2019 | 18/11/2020 | SmPC, Labelling and PL |  |
| IB/0006   | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation  | 17/06/2019 | n/a        |                        |  |
| IAIN/0007 | C.I.3.a - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Implementation of wording agreed by the competent authority | 10/05/2019 | 02/08/2019 | SmPC and PL            |  |
| IB/0005/G | This was an application for a group of variations.   | 12/03/2019 | 02/08/2019 | SmPC and PL            |  |

|           |   |            |            |             |  |
|-----------|---|------------|------------|-------------|--|
|           | <p>C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH</p> <p>C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH</p> |            |            |             |  |
| IAIN/0004 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation  | 27/11/2018 | 02/08/2019 | SmPC and PL |  |
| IB/0002   | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)   | 15/08/2018 | 02/08/2019 | SmPC        |  |
| IA/0003/G | <p>This was an application for a group of variations.</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p> <p>B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process</p>  | 10/08/2018 | n/a        |             |  |
| IB/0001/G | This was an application for a group of variations.  | 17/05/2018 | 25/06/2018 | SmPC and PL |  |

|  |   |  |  |  |  |
|--|---|--|--|--|--|
|  | <p>C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH</p> <p>C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH</p> |  |  |  |  |
|--|---|--|--|--|--|